Dr. Wang on Updated Data With Single-Agent Acalabrutinib in MCL

Michael Wang, MD
Published: Thursday, Feb 14, 2019



Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses updated data with single-agent acalabrutinib (Calquence) in relapsed/refractory mantle cell lymphoma (MCL).

At the 2018 ASH Annual Meeting, Wang presented longer-term follow-up data from the pivotal trial that led to the initial FDA approval for the second-generation BTK inhibitor in October 2017. Acalabrutinib is indicated for the treatment of adult patients with MCL who have received at least 1 prior therapy. While the initial data published in Lancet Oncology consisted of 15 months follow-up, the data presented at the meeting were from over 2 years of follow-up.

At a median follow-up of 26.3 months, the overall response rate with acalabrutinib was 81% and appeared to be consistent across subgroups based on tumor bulk. Median duration of response was 26.0 months and median progression-free survival was 20.0 months. The median overall survival (OS) was not yet reached at the time of the presentation, but the estimated 2-year OS rate was 72% with the agent. Acalabrutinib has not yet been tested in a head-to-head study with the first-generation BTK inhibitor ibrutinib (Imbruvica).
SELECTED
LANGUAGE


Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses updated data with single-agent acalabrutinib (Calquence) in relapsed/refractory mantle cell lymphoma (MCL).

At the 2018 ASH Annual Meeting, Wang presented longer-term follow-up data from the pivotal trial that led to the initial FDA approval for the second-generation BTK inhibitor in October 2017. Acalabrutinib is indicated for the treatment of adult patients with MCL who have received at least 1 prior therapy. While the initial data published in Lancet Oncology consisted of 15 months follow-up, the data presented at the meeting were from over 2 years of follow-up.

At a median follow-up of 26.3 months, the overall response rate with acalabrutinib was 81% and appeared to be consistent across subgroups based on tumor bulk. Median duration of response was 26.0 months and median progression-free survival was 20.0 months. The median overall survival (OS) was not yet reached at the time of the presentation, but the estimated 2-year OS rate was 72% with the agent. Acalabrutinib has not yet been tested in a head-to-head study with the first-generation BTK inhibitor ibrutinib (Imbruvica).



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x